Forebygging av hjerte- og karsykdom ved type 2-diabetes

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 21, 2000, Pages 2554-2559

  Birkeland, Kåre I ^a   Claudi, Tor ^g   Hansteen, Viggo ^b   Hanssen, Kristian F ^c   Hjermann, Ingvar ^d   Jenssen, Trond ^e   Jervell, Jak ^e   Os, Ingrid ^f  

^a Hormonlaboratoriet   (Norway)

^b Kardiologisk Avdeling   (Norway)

^c Endokrinologisk Avdeling   (Norway)

^d Avdeling for Preventiv Kardiologi   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Nyremedisinsk Avdeling   (Norway)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

CARDIOVASCULAR DISEASE; EXERCISE; FEEDING BEHAVIOR; HEALTH SERVICE; HUMAN; LIFESTYLE; METABOLISM; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SMOKING CESSATION;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIETARY SERVICES; EXERCISE; FOOD HABITS; HUMANS; LIFE STYLE; PRACTICE GUIDELINES; RISK FACTORS; SMOKING CESSATION;

EID: 0034633123     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
2. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.
3. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8.
4. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-8.
5. Report of a WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Genève: WHO, 1999.
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
7. The HOPE Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.
8. Wood D, Backer GD, Faergeman O, Graham I, Mancia G, Pyörälä K et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-503.
9. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabet Med 1999; 16: 219-27.
10. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabestes (UKPDS 33). Lancet 1998; 352: 837-53.
11. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
12. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovaskular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
13. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
14. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res 1997; 34: 248-53.
15. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-68.
16. Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 1995; 310: 560-4.
17. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-6.
18. Eriksson KF, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998; 41: 1010-6.
19. Anderssen SA, Hjermann I, Urdal P, Torjesen PA, Holme I. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the «atherothrombogenic syndrome». Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med 1996; 240: 203-9.
20. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999; 22: 1887-98.
21. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-28.
22. Facchini FS, Hollenbeck CB, Jeppesen J, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-30.
23. Feskens EJ, Kromhout D. Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle aged men. Am J Epidemiol 1989; 130: 1101-8.
24. Chaturvedi N, Sztevens L, Fuller JH. Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Multinational Study Group. Diabetes Care 1997; 20: 1266-73.
25. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.
26. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.
27. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38.
28. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
29. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-84.
30. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
31. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
32. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749-56.
33. The Antiplatelet Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
34. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
35. The CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 93: 2513-9.
36. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
37. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-5.
38. Elkeles R, Diamond J, Poulter C, Dhanjil S, Nicolaides A, Mahmood S et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641-8.
39. Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
40. Bang H, Dyerberg J, Hjørne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand 1976; 200: 69-73.
41. Simopoulos A. Omega-3 fatty acids in the prevention-management of cardiovascular disease. Can J Physiol Pharmacol 1997; 75: 234-9.
42. The GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.
43. Toft I, Bønaa K, Ingebretsen O, Nordøy A, Jenssen T. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. Ann Intern Med 1995; 123: 911-18.
44. Nordøy A, Bønaa K, Nilsen H, Berge R, Hansen J, Ingebretsen O. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 1998; 243: 163-70.
45. Hetlevik I, Holmen J, Midthjell K. Treatment of diabetes mellitus - physicians' adherence to clinical guidelines in Norway. Scand J Prim Health Care 1997; 15: 193-7.